<DOC>
	<DOCNO>NCT00588445</DOCNO>
	<brief_summary>The purpose research study : - see gefitinib pill shrink Stage 1 2 non-small cell lung cancer surgery - see non-small cell lung cancer mutation certain part EGFR gene - see patient whose tumor shrink gefitinib treatment likely mutation certain part EGFR gene - see pattern protein expression blood related tumor 's sensitivity resistance gefitinib treatment . - see expression certain gene tumor relate tumor 's sensitivity resistance gefitinib treatment .</brief_summary>
	<brief_title>Phase II Trial Correlate Radiographic Response Induced By Gefitinib With Mutations Protein-Tyrosine Kinase Domain EGF Receptor Gene</brief_title>
	<detailed_description>This phase II , single institution trial correlate gefitinib response mutation protein-tyrosine kinase domain EGF receptor gene . The study conduct patient Stage I II NSCLC determine operable resectable . Patients must 1 follow feature : never smoker smoke history &lt; 15 pack year and/or feature bronchioloalveolar lung cancer . 50 patient enrol study . Treatment gefitinib least 21 day surgery ( depend time surgery ) . Patients discontinue gefitinib 2 day operation . For patient demonstrate radiographic response gefitinib preoperatively /or patient mutation protein-tyrosine kinase domain EGF receptor gene ( identified surgical sample ) , gefitinib continue 2 year post-surgery . Patients evidence radiographic response mutation protein-tyrosine kinase domain EGF receptor gene remove study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Pathologic confirmation malignancy Memorial SloanKettering Patients must previously untreated stage I II NSCLC ( T112N0M0 , T12N1M0 , T3N0M0 ) 1 follow feature : never smoker &lt; 15 pack year smoke history and/or bronchioloalveolar cancer ( either pure BAC , BAC focal invasion adenocarcinoma BAC feature ) Patients must determine operable resectable treat thoracic surgeon . Age &gt; 18 year . Measurable indicator lesion Ability understand willingness sign write informed consent document . Pregnant lactate woman woman childbearing potential use effective contraception . Men participate trial must also use effective contraception sexually active . Patients may receive investigational agent . Any history evidence interstitial lung disease ( patient chronic stable radiographic change asymptomatic need exclude ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Gefitnib</keyword>
	<keyword>Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>bronchioloalveolar cancer</keyword>
	<keyword>smoker</keyword>
</DOC>